Sanofi is preparing a phase 3 programme for asthma candidate amlitelimab, despite mixed data in a phase 2 trial.

Roche is moving its novel antibiotic zosurabalpin into phase 3 testing for carbapenem-resistant Acinetobacter baumannii (CRAB), a 'superbug' that is considered an 'urgent threat' by the CDC, in ...